Invex Therapeutics Ltd (ASX:IXC)

Australia · Delayed Price · Currency is AUD

0.1100

0.00 (0.00%)

At close: Oct 6, 2026

Market Cap	8.27M -8.3%
Revenue (ttm)	46.83K -79.6%
Net Income	-1.35M
EPS	-0.02
Shares Out	75.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55
Open	0.1100
Previous Close	n/a
Day's Range	0.1100 - 0.1100
52-Week Range	0.0900 - 0.1500
Beta	0.52
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 27, 2026

About Invex Therapeutics

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based i... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2019

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol IXC

Full Company Profile

Financial Performance

In fiscal year 2026, Invex Therapeutics's revenue was 46,826, a decrease of -79.56% compared to the previous year's 229,084. Losses were -1.35 million, 183.6% more than in 2025.

Financial Statements